Genmab — Oktober 2023
-
og uge kortet https://www.proinvestor.com/boards/112093/$/115971
-
Novo Nordisk-direktør satser på vækst inden for sjældne sygdomme https://medwatch.dk/Medicinal___Biotek/article16490656.ece?utm_medium=latestNews Han fortæller desuden, at væksten skal bæres af fire nye produkter, hvoraf Mim8, er udviklet i samarbejde med Genmab, der ventes at kommet til at stå for ...
-
Janssen Submits Application to the European Medicines Agency for RYBREVANT
▼ (amivantamab) in Combination with Chemotherapy for the First-Line Treatment of Adult Patients with Advanced Non-Small Cell Lung Cancer with Activating EGFR Exon 20 Insertion Mutations https://www.globenewswire.com/news-release/2023/10/06/2755961/0/en/Janssen-Submits-Application-to-the-European-Medicines-Agency-for-RYBREVANT-amivantamab-in-Combination-with-Chemotherapy-for-the-First-Line-Treatment-of-Adult-Patients-with- -
AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC https://www.prnewswire.com/news-releases/amgen-completes-acquisition-of-horizon-therapeutics-plc-301949517.html --> let's start that Tepezza push
-
Rapport fra Stifel omkring situtationen for biotek https://www.proinvestor.com/boards/115979
-
Tepkinly European public assessment report if you really have nothing to do this weekend https://www.ema.europa.eu/en/medicines/human/EPAR/tepkinly
Det er ikke store ord, de bruger om de foreløbige resultater: tolerabel sikkerhedsprofil og påvist klinisk aktivitet.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind